{"groups":[{"description":"Participants received pirtobrutinib 200 milligrams (mg) orally once daily in continuous 28-day cycles until disease progression or unacceptable toxicity.","id":"FG000","title":"Arm A - Pirtobrutinib"},{"description":"Participants received bendamustine 90 milligrams per square meter (mg/m²) intravenously on Days 1 and 2 of each 28-day cycle (Cycles 1-6) plus rituximab 375 mg/m² intravenously on Cycle 1 Day 1, then 500 mg/m² on Day 1 of Cycles 2-6. Eligible participants in Arm B crossed over to receive pirtobrutinib following independent review committee (IRC)-confirmed progressive disease (PD).","id":"FG001","title":"Arm B - Bendamustine Plus Rituximab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"130"},{"groupId":"FG001","numSubjects":"108"}],"type":"On study"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"10"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"19"}],"type":"Withdrawal of consent"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Sponsor Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participant did not agree to full active follow-up visits"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participant denied doing more than one computerized axial tomography test per year"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"141"},{"groupId":"FG001","numSubjects":"141"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"140"},{"groupId":"FG001","numSubjects":"132"}],"type":"Received at Least One Dose of Study Drug (Including a Partial Dose)"},{"achievements":[{"comment":"This milestone is not applicable for Arm A.","groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"18"}],"comment":"As per the planned analysis, Adverse Events were monitored separately for this group, and the data has been reported accordingly in the Adverse Events section.","type":"Arm B Participants Who Crossed Over to Receive Pirtobrutinib"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"141"},{"groupId":"FG001","numSubjects":"141"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}